WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...
As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...
Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...
Severe exacerbation occurred in 5.1% of patients taking albuterol/budesonide compared with 9.1% of patients taking albuterol alone in the on-treatment efficacy population. Albuterol/budesonide ...
If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...
Some people with asthma need to use multiple inhaled medicines to keep their symptoms under control. Some inhaled medicines can be used on a regular basis to manage symptoms. Other inhaled medicines, ...
Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...
The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...
There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results